Apothecary Shops changing brand to Avella Specialty Pharmacy in August
PHOENIX — The Apothecary Shops are rebranding to become Avella Specialty Pharmacy, effective in August, the company announced Wednesday.
"We are rebranding to establish a single entity that more accurately represents the evolution of our company," stated Keith Cook, president of Avella Specialty/Apothecary Shops. "In doing so, we anticipate it will be easier for customers and partners to communicate with us."
The letters within Avella are selected from key words in the company’s mission statement: Health, Devotion and Excellence. The new infinity logo illustrates the continuous and uninterrupted commitment to patients and providers.
"Our company fundamentals have not changed. We have the same leadership, store locations and commitment to clinical excellence and patient care," Cook said.
A new brand video and updated registration is available at the company’s new website at Avella.com.
Similasan signs PR firm GroundFloor Media as agency of record
DENVER — GroundFloor Media — a Denver-based, integrated agency focusing on strategic communications, social media, reputation and crisis management, and digital strategy — on Thursday announced Similasan USA as the newest addition to its client roster.
Similasan offers a variety of products in several key categories, including eye care, ear care, allergy relief and pediatric remedies.
“We are very pleased to have the opportunity to work with Similasan USA as their public relations agency of record, and look forward to leveraging our experience in health-and-wellness and consumer products to help build awareness for their exceptional line of products,” stated Laura Love, president GFM.
Kadmon announces launch of 600 mg/day dose pack of Ribasphere RibaPak
NEW YORK — Kadmon Pharmaceuticals earlier this month announced that it has launched a new 600 mg/day dose pack of Ribasphere RibaPak (ribavirin, USP), Kadmon’s proprietary ribavirin regimen available in a daily, two-pill compliance package for enhanced therapy adherence.
The new dose pack is designed to provide added dosing control to improve the management of hemolytic anemia in certain patients prescribed the triple therapy of a protease inhibitor, pegylated alpha interferon and ribavirin for the treatment of chronic hepatitis C virus infection.
"Anemia, particularly severe anemia, is an important concern with hepatitis C treatments, one which may be effectively controlled through ribavirin dose reduction," stated John Ryan, EVP and chief medical officer of Kadmon. "Anemia can also affect treatment adherence and a patient’s ability to complete therapy. The new 600 mg/day Ribasphere RibaPak dose pack ensures that physicians can seamlessly reduce ribavirin dose without compromising the adherence advantages of RibaPak."
Pooled data from studies of the protease inhibitors Victrelis (boceprevir) and Incivek (telaprevir), approved in 2011 for the treatment of genotype 1 chronic hepatitis C virus, showed that anemia was a frequently observed adverse event in both treatment-naive and treatment-experienced patients, in some cases exhibiting a doubling of incidence over control (peginterferon/ribavirin). In clinical studies, anemia has been managed with ribavirin dose reduction and/or with off-label use of erythropoietin.
With the new 600 mg/day dose pack, Ribasphere RibaPak now is available in four dosing options: 600 mg/day, 800 mg/day, 1,000 mg/day and 1,200 mg/day. Ribasphere RibaPak offers a unique packaging and dosage form designed to simplify treatment, reducing ribavirin pill burden by up to 66% over a 48-week course of treatment, and to make it easier for the patient to keep track of his or her treatment.
Adherence to therapy is an important component in the successful treatment of hepatitis C. The risk of noncompliance includes treatment failure or relapse and, because of the direct antiviral mechanism of protease inhibitors, missed doses of a protease inhibitor could lead to viral resistance.